Neumora Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
490 Arsenal Way Ste 200, Watertown, Mass...Phone Number
(857) 760-0900Website
www.neumoratx.comRevenue
-Stock Symbol
NMRAIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About Neumora Therapeutics
Neumora was founded to improve the lives of patients with brain diseases. A significant challenge is a lack of targeted, effective medicines.Explore more
Neumora Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neumora Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Neumora Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Neumora Therapeutics
Product Launch: Get notified when Neumora Therapeutics launches new products
Neumora Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Neumora Therapeutics had a recent Job posting/layoffs
Check if Neumora Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Neumora Therapeutics has new funding data
Earning: See what the market has to say on Neumora Therapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Neumora Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Neumora Therapeutics
Compare insights from companies similar to Neumora Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Neumora Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Neumora Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Neumora Therapeutics.
Neumora Therapeutics financials insights
Gather financial insights about Neumora Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$500M
2022
Series B
$112M
Neumora Therapeutics Tech Stack
A closer look at the technologies used by Neumora Therapeutics
See more technologies
Most Recent Scoops
Project
Neumora Therapeutics has reported that its medical monitoring and SAFR process have achieved approximately two-thirds female patient enrollment consistent with its target and a significantly higher screen fail rate, providing the company sufficient confidence to invest additional capital and maximize patient enrollment in KOASTAL-2 and KOASTAL-3.
Spending/Investment, Clinical Operations
Project
Neumora Therapeutics has reported Phase Ib study results for NMRA-511 in patients with Alzheimer's disease agitation, demonstrating a mild side effect profile and efficacy across multiple measures including CMAI, CGI-S, and NPI comparable to REXULTI within a similar patient population, characterizing NMRA-511 as a potentially safer alternative with a comparable efficacy profile.
Medical Research
Pain Point
reported that results from KOASTAL-1, received in early 2025, revealed an overly inflated placebo response particularly in the male population attributed to inappropriate patient selection.
Medical Research, Clinical Operations
Partnership
Neumora Therapeutics has partnered with Massachusetts General Hospital and its SAFR program, led by Maurizio Fava, to provide medical monitoring and ensure appropriate patient enrollment in the KOASTAL-2 and KOASTAL-3 studies, with amendments implemented in early 2025.
Partnership, Medical Research, Clinical Operations
Pain Point
Medical Research
Neumora Therapeutics News & Media
Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)
Neumora Therapeutics reported data from its Phase 3 KOASTAL Program; the stock fell nearly 50%. NEW YORK, June 16, 2026 /PRNewswire/ -- Neumora Therapeutics (NASDAQ: NMRA) shareholders lost significant value today after the company disclosed that navacaprant failed both Phase 3 KOASTAL-2...NMRA INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Neumora Therapeutics, Inc.
ATLANTA, June 15, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Neumora Therapeutics, Inc. (“Neumora” or the “Company”) (NASDAQ: NMRA) complied with federal securities laws. On June 15, 2026, Neumora announced that “the Phase 3 KOASTAL-2 and -3 studies of navacaprant for the treatment of major depressive disorder (MDD) did not achieve statistical significance on the primary or key secondary endpoints.” Neumora is discontinuing development of navacaprant and reducing itsNeumora Ends Phase 3 KOASTAL Study Of Navacaprant, To Lay Off 35% Of Workforce
Neumora Therapeutics Inc. (NMRA), a clinical-stage biopharmaceutical company, on Monday announced the discontinuation of the Phase 3 KOASTAL program evaluating Navacaprant for the treatment of major depressive disorder.Neumora discards depression asset, lays off staffers after pair of late-stage flops - BioSpace
Neumora Therapeutics is laying off 35% of workers after its most advanced asset failed a pair of Phase 3 studies, sending the biotech’s stock spiraling early Monday.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Neumora Therapeutics
Sign Up For FreeTo access detailed company insights
Neumora was founded to improve the lives of patients with brain diseases. A significant challenge is a lack of targeted, effective medicines.... Read More
